Protocol for Identifying Patients at Risk of AKI
Researchers at Aintree University Hospital (Liverpool, UK) noted that AKI has a mortality rate of 30 percent, which is higher than that for myocardial infarction (8 percent) and stroke (9 percent). They estimated that 15 percent of all inpatients at Aintree University Hospital suffer an AKI, “making it a condition of considerable importance in everyday practice.”
To reduce the toll of AKI at the hospital, and raise awareness of the importance of its prevention, co-authors Thangavelu Chandrasekar, MRCP, and Hsu Pheen Chong, MbChB, developed the STOP-AKI protocol. The programme uses automated electronic alerts to identify patients at risk for developing AKI. STOP-AKI was initially launched in the nephrology ward and then scaled up to become part of routine management for all patients admitted to the hospital.
The researchers used a multidisciplinary streamlined approach, incorporating AKI risk assessment and screening for prevention, early detection using automated e-alerts, and effective intervention (using an evidence-based AKI treatment bundle) to improve patient outcomes by reducing the AKI-associated mortality by 23 percent. At the same time, hospital length of stay fell by 13 percent, or a 2.7-day reduction in length of stay.
See Also: Global Study: 65% of AKI Cases Are Community Acquired
“Improving staff and patient awareness through education, effective monitoring, and handover to primary care on discharge has ensured continuity of care that will hopefully reduce readmissions with AKI,” explained Dr. Chandrasekar. He noted that this required multiple changes to the system at different levels to achieve the reductions in mortality and hospital length of stay.
The research team is currently developing metrics to assess AKI progression and its predictors. They have also rolled out STOP-AKI alerts and management guidelines to the community, enabling much earlier intervention, Dr. Chandrasekar added.
The STOP-AKI protocol is one of several Avoidable Mortality Reduction projects underway at Aintree University Hospital, the others focusing on reducing sepsis and pneumonia.
Source: American Society of Nephrology
Image credit: London Acute Kidney Injury Network
Published on : Sun, 8 Nov 2015
Print as PDF
NovaPort cannulas are designed specially to meet the needs of extracorporeal lung and heart support circuits and perioperative perfusion in minimally invasive heart surgery.All blood-contact surfaces of the NovaPort cannulas are coated with the bio- and...
FeaturesMindray BeneVision Central Monitoring System is a powerful and scalable solution providing for continuous, real-time surveillance across networks large and small. The system can display patient information from networked monitors, wireless transport...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
Features The SynoVent E5 is the ventilator you need with the interface you want. It does not only include advanced ventilator functionality for patients ranging from infant to adult, but also a modern, easy-to-use interface. The display can be configured...
The HAMILTON-C3 ventilator is a modular high-end ventilation solution for all patient groups. Offering a number of unique features, the HAMILTON-C3 is one of the first ventilators featuring the “Ventilation Autopilot” INTELLiVENT-ASV®. The HAMILTON-C3’s...